CFB siRNA therapy (Argo Biopharma)

N/A

Report date: 2025/06/11 10:35:32

NME

Base Information

Drug NameCFB siRNA therapy (Argo Biopharma)

Drug Alias NameN/A

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA

Mechanisms of ActionComplement factor B expression inhibitors

TargetsComplement factor B

Therapy Area/IndicationsHemoglobinuria, ParoxysmalGlomerulonephritis, IGAMyasthenia Gravis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesShanghai Argo Biopharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Argo Biopharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsHemoglobinuria, ParoxysmalGlomerulonephritis, IGAMyasthenia Gravis

Inactive IndicationsN/A

Other Information

ATC CodeN/A